Know a great AI tool or AI news source? Submit it to AiByts
NeoCOAST-25 min read

ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2

Patients with resectable non-small cell lung cancer (NSCLC) remain at high risk of relapse despite perioperative treatment1-3. NeoCOAST-2 (NCT05061550), a phase 2, randomised platform trial, tested novel perioperative treatments in patients with stage IIA–IIIB NSCLC.

By Lara McGrathNature AI

Read the full story

Originally published by Nature AI on Oct 25, 2026.

Read on Nature AI(opens in a new tab)

Comments

Sign in to join the discussion.

No comments yet — be the first to share your thoughts.